1️⃣ Odyssey reopened the biotech IPO window a little
Odyssey Therapeutics moved to Nasdaq with an upsized IPO, with Fierce reporting $304M to fund autoimmune and inflammatory programs.
💡 Why it matters
Biotech public capital is still selective, but investors are paying for platform depth when the pipeline has near-term clinical use of proceeds.
☕ Coffee talk
How many private immunology platforms now test the window instead of waiting for pharma?
2️⃣ FDA just softened the Ebvallo single-arm problem
Atara said FDA agreed that a pre-specified single-arm study with an appropriate historical control could support a future tab-cel marketing application.
💡 Why it matters
This is not an approval. It is still a useful signal for rare-disease assets where randomized trials are hard, slow or commercially unrealistic.
☕ Coffee talk
Who else with a bruised rare-disease file now asks for the same meeting?
3️⃣ FDA is turning inspections into a faster screen
FDA has started one-day inspectional assessments across biologics, medical products and clinical research programs, with about 46 completed by late April.
💡 Why it matters
Lower-risk sites may get quicker feedback, but the agency also gets more facility data for risk scoring. That changes how quality risk is surfaced before the full inspection.
☕ Coffee talk
Which CDMOs are actually low-risk once FDA starts comparing the registered site to the real one?